New CAR T-Cell Therapy Finds Niche in R/R Mantle Cell Lymphoma

Pam Harrison

April 07, 2020

A single infusion of a new chimeric antigen receptor (CAR) T-cell therapy has showed durable remissions in patients with relapsed or refractory mantle cell lymphoma who had stopped responding to Bruton's tyrosine kinase (BTK) inhibitor therapy.

These patients "have a very poor prognosis," note the authors, led by Michael Wang, MD, professor of lymphoma and myeloma at the University of Texas MD Anderson Cancer Center in Houston. They represent a therapeutic challenge, the authors add, and retrospective studies evaluating salvage therapy have shown low response rates and a median overall survival of 6 to 10 months.

In contrast, the results they now report with the investigational anti-CD19 CAR T-cell therapy, KTE-X19 (Kite Pharma, now part of Gilead), show that 63 (85%) of 74 patients in the intention-to-treat analysis had an objective response, and 59% of patients achieved a complete response (CR).

These results come from the ZUMA-2 phase 2 multicenter trial and were published in the April 2 issue of the New England Journal of Medicine.

"Our reported results, including a manageable safety profile, point to this therapy as an effective and viable option for patients with relapsed or refractory mantle cell lymphoma," Wang said in a statement.

KTE-X19 is awaiting approval in the United States for use in mantle cell lymphoma, with a decision expected in August. It could be the third CAR T cell to reach the market, but the first for this indication.

Heavily Pretreated Patients

The ZUMA-2 trial involved 74 patients with relapsed or refractory mantle cell lymphoma. They had received up to five previous lines of therapy, including BTK inhibitor therapy with either ibrutinib (Imbruvica, Pharmacyclics/Janssen) or acalabrutinib (Calquence,AstraZeneca).

"All the patients underwent leukapheresis to obtain cells for KTE-X19 manufacturing," the authors note.

KTE-X19 was successfully manufactured for 96% of patients and 92% of patients actually received the single infusion.

"The median time from leukapheresis to the delivery of KTE-X19…was 16 days," the authors note.

Before receiving the CAR T cell, patients received a conditioning chemotherapy consisting of fludarabine and cyclophosphamide, given on days -5, -4, and -3 prior to receiving a single intravenous infusion of KTE-X19, at a dose of 2x106 CAR T cells/kg of body weight on day 0. 

For the primary efficacy analysis, the median follow-up was 12.3 months.

Among all 74 enrolled patients who made up the intention-to-treat analysis, 85% had an objective response — the primary endpoint of the study — with 59% of patients achieving a complete response (CR).

"The median time to an initial response was 1.0 month…and the median time to a complete response was 3.0 months," Wang and colleagues report.

Of those who achieved either a partial response or whose disease stabilized following the infusion, 57% achieved a CR after a median of 2.2 months.

Moreover, among protocol-specified patients (n = 60), a single infusion of KTE-X19 led to an objective response in 93% of patients and a CR of 67%.

At 12 months, estimated progression-free survival (PFS) was 61% and overall survival was 83%. PFS rates at 6 months were equivalent among patients with poor prognostic features as well, as investigators pointed out.

Some 57% of patients in the primary efficacy analysis and 78% of patients who achieved a CR continued to respond to treatment after a median follow-up of 12.3 months.

Adverse Events

As has been seen with other CAR T-cell therapies, this product also had serious and life-threatening toxic events, the authors note, but they add that in this trial no patient died as a result. 

Adverse events (AEs) of grade 3 or higher occurred in virtually all patients,  Wang and colleagues note. Most commonly, these involved cytopenias (94% of patients) and infections (32%).

Further, cytokine release syndrome (CRS), a well-recognized AE of all CAR T-cell therapy, occurred in 91% of patients; however, no patient died of CRS and most episodes were grades 1 and 2.

When CRS occurred, 59% of patients received treatment with the interleukin-6 inhibitor tocilizumab (Actemra, Genentech) and all events resolved within a median of 11 days.

A total of 63% of patients also developed a neurologic event. None were fatal, but grade 3 or higher neurologic events were seen in 31% of patients. Grade 3 or higher infections also occurred in about one third of patients, the most common being pneumonia.

The study was funded by Kite Pharma, a Gilead company. Wang reports he has received research support and has served on the advisory board and as a consultant for Kite Pharma.

N Eng J Med. Published online April 2, 2020. Abstract

For more from Medscape Oncology, join us on Twitter and Facebook.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.